TWI536992B - And a medicinal composition for oral administration of improved elution and / or absorption - Google Patents
And a medicinal composition for oral administration of improved elution and / or absorption Download PDFInfo
- Publication number
- TWI536992B TWI536992B TW102133892A TW102133892A TWI536992B TW I536992 B TWI536992 B TW I536992B TW 102133892 A TW102133892 A TW 102133892A TW 102133892 A TW102133892 A TW 102133892A TW I536992 B TWI536992 B TW I536992B
- Authority
- TW
- Taiwan
- Prior art keywords
- pharmaceutical composition
- acidic additive
- carbonylpiperidin
- polin
- methylpyrrol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012205681 | 2012-09-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201414476A TW201414476A (zh) | 2014-04-16 |
| TWI536992B true TWI536992B (zh) | 2016-06-11 |
Family
ID=50341439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW102133892A TWI536992B (zh) | 2012-09-19 | 2013-09-18 | And a medicinal composition for oral administration of improved elution and / or absorption |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9555115B2 (es) |
| EP (1) | EP2898886B1 (es) |
| JP (1) | JP5791817B2 (es) |
| KR (1) | KR101609105B1 (es) |
| CN (1) | CN104640547B (es) |
| AU (1) | AU2013319118B2 (es) |
| BR (1) | BR112015005489B1 (es) |
| CA (1) | CA2884731C (es) |
| DK (1) | DK2898886T3 (es) |
| ES (1) | ES2622585T3 (es) |
| HK (1) | HK1207969A1 (es) |
| HU (1) | HUE032635T2 (es) |
| MX (1) | MX345435B (es) |
| MY (1) | MY183976A (es) |
| PL (1) | PL2898886T3 (es) |
| PT (1) | PT2898886T (es) |
| RU (1) | RU2589701C1 (es) |
| SG (1) | SG11201501043TA (es) |
| TW (1) | TWI536992B (es) |
| WO (1) | WO2014046129A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI707851B (zh) * | 2015-09-17 | 2020-10-21 | 日商大鵬藥品工業股份有限公司 | 哌嗪化合物的新穎結晶 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3237575A1 (de) | 1982-10-09 | 1984-04-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale mopidamolformen |
| JP4292588B2 (ja) * | 1997-01-31 | 2009-07-08 | 日産化学工業株式会社 | ピリダジノン化合物類の経口製剤 |
| TW482675B (en) | 1997-01-31 | 2002-04-11 | Green Cross Corp | Compositions for oral administration containing pyridazinone compounds technical field of the invention |
| JP3797764B2 (ja) | 1997-10-01 | 2006-07-19 | エーザイ株式会社 | 光安定化組成物 |
| KR100909665B1 (ko) * | 2000-12-21 | 2009-07-29 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 약제학적 조성물 |
| JP2004528345A (ja) * | 2001-04-30 | 2004-09-16 | シャイア ラボラトリーズ，インコーポレイテッド | Ａｃｅ／ｎｅｐインヒビターおよびバイオアベイラビリティーエンハンサーを含む薬学的組成物 |
| US20040137052A1 (en) | 2001-12-25 | 2004-07-15 | Yoshihiro Uchiyama | Acid-containing preparations |
| JP2003252762A (ja) * | 2001-12-25 | 2003-09-10 | Takeda Chem Ind Ltd | 酸配合製剤 |
| DE10209982A1 (de) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma | Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe |
| DE10337697A1 (de) * | 2003-08-16 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze |
| JP4572293B2 (ja) | 2004-07-21 | 2010-11-04 | トーアエイヨー株式会社 | ピモベンダン経口投与製剤 |
| RU2434630C2 (ru) * | 2006-08-31 | 2011-11-27 | Юранд, Инк. | Системы доставки лекарственных средств, включающие в себя твердые растворы слабоосновных лекарственных средств |
| NZ579851A (en) | 2007-03-28 | 2012-02-24 | Takeda Pharmaceutical | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a ph control agent |
| KR101520311B1 (ko) | 2007-05-21 | 2015-05-14 | 도레이 카부시키가이샤 | 특정 유기산을 함유하는 경구 제제, 및 경구 제제의 용출성과 화학적 안정성의 개선 방법 |
| MX2010013355A (es) | 2008-06-04 | 2010-12-21 | Astrazeneca Ab | Nuevos compuestos v. |
| PE20110591A1 (es) | 2008-07-28 | 2011-09-15 | Takeda Pharmaceutical | Composicion farmaceutica estabilizada a base de un compuesto no peptidico |
| WO2010100759A1 (ja) | 2009-03-06 | 2010-09-10 | トヨタ自動車株式会社 | 運転支援装置 |
| CN102341385B (zh) * | 2009-03-09 | 2014-01-15 | 大鹏药品工业株式会社 | 能够抑制前列腺素d合酶的哌嗪化合物 |
-
2013
- 2013-09-18 KR KR1020157009713A patent/KR101609105B1/ko active IP Right Grant
- 2013-09-18 MY MYPI2015700813A patent/MY183976A/en unknown
- 2013-09-18 MX MX2015003410A patent/MX345435B/es active IP Right Grant
- 2013-09-18 CA CA2884731A patent/CA2884731C/en active Active
- 2013-09-18 TW TW102133892A patent/TWI536992B/zh active
- 2013-09-18 RU RU2015114567/15A patent/RU2589701C1/ru active
- 2013-09-18 EP EP13839200.6A patent/EP2898886B1/en active Active
- 2013-09-18 DK DK13839200.6T patent/DK2898886T3/en active
- 2013-09-18 PT PT138392006T patent/PT2898886T/pt unknown
- 2013-09-18 CN CN201380048719.6A patent/CN104640547B/zh active Active
- 2013-09-18 PL PL13839200T patent/PL2898886T3/pl unknown
- 2013-09-18 JP JP2014536878A patent/JP5791817B2/ja active Active
- 2013-09-18 SG SG11201501043TA patent/SG11201501043TA/en unknown
- 2013-09-18 WO PCT/JP2013/075157 patent/WO2014046129A1/ja active Application Filing
- 2013-09-18 BR BR112015005489-7A patent/BR112015005489B1/pt active IP Right Grant
- 2013-09-18 ES ES13839200.6T patent/ES2622585T3/es active Active
- 2013-09-18 AU AU2013319118A patent/AU2013319118B2/en active Active
- 2013-09-18 US US14/423,750 patent/US9555115B2/en active Active
- 2013-09-18 HU HUE13839200A patent/HUE032635T2/en unknown
-
2015
- 2015-09-02 HK HK15108589.3A patent/HK1207969A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY183976A (en) | 2021-03-17 |
| KR20150056827A (ko) | 2015-05-27 |
| EP2898886A4 (en) | 2016-04-27 |
| HUE032635T2 (en) | 2017-10-30 |
| PT2898886T (pt) | 2017-03-23 |
| WO2014046129A1 (ja) | 2014-03-27 |
| KR101609105B1 (ko) | 2016-04-04 |
| PL2898886T3 (pl) | 2017-06-30 |
| BR112015005489B1 (pt) | 2022-07-12 |
| AU2013319118A1 (en) | 2015-03-12 |
| BR112015005489A2 (pt) | 2017-07-04 |
| US9555115B2 (en) | 2017-01-31 |
| ES2622585T3 (es) | 2017-07-06 |
| EP2898886B1 (en) | 2017-02-15 |
| CN104640547A (zh) | 2015-05-20 |
| CN104640547B (zh) | 2017-07-11 |
| AU2013319118B2 (en) | 2016-03-03 |
| SG11201501043TA (en) | 2015-04-29 |
| JPWO2014046129A1 (ja) | 2016-08-18 |
| EP2898886A1 (en) | 2015-07-29 |
| MX2015003410A (es) | 2015-06-04 |
| RU2589701C1 (ru) | 2016-07-10 |
| US20150297722A1 (en) | 2015-10-22 |
| CA2884731C (en) | 2016-11-01 |
| DK2898886T3 (en) | 2017-03-27 |
| TW201414476A (zh) | 2014-04-16 |
| CA2884731A1 (en) | 2014-03-27 |
| HK1207969A1 (en) | 2016-02-19 |
| MX345435B (es) | 2017-01-30 |
| JP5791817B2 (ja) | 2015-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2006257072A1 (en) | Diclofenac formulations and methods of use | |
| US20160045440A1 (en) | FORMULATION OF AMORPHOUS CALCIUM L-5-METHYLTETRAHYDROFOLATE (L-5-MTHF-Ca) | |
| JP4853818B2 (ja) | イブプロフェン及び塩酸アンブロキソール含有固形製剤 | |
| JP2016104812A (ja) | ロキソプロフェンナトリウム及びトラネキサム酸を含有する固形製剤 | |
| WO2005099698A1 (ja) | 安定化された４－アミノ－５－クロロ－Ｎ－［（１Ｒ，３ｒ，５Ｓ）－８－メチル－８－アザビシクロ［３．２．１］オクタ－３－イル]－２－［１－メチルブタ－２－インイルオキシ］ベンズアミド含有組成物 | |
| JP6590822B2 (ja) | 縮合アミノジヒドロチアジン誘導体の医薬組成物 | |
| TWI536992B (zh) | And a medicinal composition for oral administration of improved elution and / or absorption | |
| JP7370126B2 (ja) | エルロチニブを有効成分とする医薬錠剤 | |
| JP6993765B2 (ja) | 滑らかな表面を有するフィルムコーティング錠 | |
| TW201431553A (zh) | Ｎ－［５－［２－（３，５－二甲氧基苯基）乙基］－２ｈ－吡唑－３－基］－４－［（３ｒ，５ｓ）－３，５－二甲基哌□－１－基］苯甲醯胺之醫藥調配物 | |
| JPWO2015199115A1 (ja) | 経口投与用医薬組成物 | |
| WO2022024979A1 (ja) | ミロガバリンベシル酸塩を含有する口腔内崩壊錠 | |
| JP5321454B2 (ja) | 医薬錠剤の製造法 | |
| WO2019030773A1 (en) | DICLOFENAC COMPOSITIONS WITH LOW DOSE | |
| JP2006265183A (ja) | ペルゴリド錠剤の製造方法 | |
| JP2019059685A (ja) | エルロチニブを有効成分とする医薬錠剤 | |
| JP2003300874A (ja) | 塩酸プソイドエフェドリン含有固形製剤 | |
| JP2011153119A (ja) | バンコマイシンまたはその塩を含有する錠剤 |